DROPIZOL Oral drops, solution Ref.[9176] Active ingredients: Opium

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2017  Publisher: Pharmanovia A/S, Jægersborg Allé 164, DK-2820 Gentofte, Denmark, Tel: +45 3333 7633, Fax: +45 3332 3107, e-mail: info@pharmanovia.com


Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

  • Opiate dependency.
  • Glaucoma.
  • Severe hepatic or renal impairment.
  • Delirium tremens.
  • Severe head trauma.
  • Risk of paralytic ileus.

Special warnings and precautions for use

Dropizol should only be used following investigations of the etiology causing the symptoms and when first-line treatment has not given adequate results.

Dropizol drops should be used with caution in the following conditions/for the following patients:

  • The elderly
  • Respiratory insufficiency (e.g. acute respiratory depression or Chronic Obstructive Airways Disease or asthma attack)
  • Chronic renal disease and/or hepatic disease.
  • Alcoholism.
  • Biliary colic, cholelithiasis, biliary duct diseases
  • Head injuries or increased intracranial pressure
  • Reduced consciousness
  • Heart failure secondary to lung disease
  • Cardiorespiratory shock
  • Monoamine oxidase inhibitors (including moclobemide), or within two weeks of their withdrawal
  • Adrenocortical deficiency
  • Hypothyroidism
  • Low blood pressure with hypovolaemia
  • Pancreatitis
  • Prostatic hyperplasia and other conditions predisposing to urinary retention

A health care professional should be contacted in case of difficulty to urinate.

Adjustment of dose may be needed in the elderly, patients with thyroid insufficiency, and patients with mild to moderate renal or hepatic impairment (see also section 4.2 and 4.3).

Anti-diarrheals inhibiting peristalsis should be used with caution in patients with infection or inflammatory bowel diseases due to the increased risk of absorption of toxins, and of developing toxic megacolon and intestinal perforation. Due to the risk of paralytic ileus, Dropizol is not recommended before a surgical operation or within 24 hours after operation. If paralytic ileus is suspected during the use of Dropizol, the treatment must be stopped immediately.

Repeated administration may cause dependence and tolerance and the use of opium may lead to addiction to the substance. Particular caution should be exercised in individuals predisposed to addiction to narcotics and alcohol.

Administer at reduced doses and with the utmost caution to patients who are also being treated with other narcotic agents, sedatives, and tricyclic antidepressants and MAO-inhibitors (see also section 4.2).

Should only be used with caution in patients in high-risk groups, such as patients with epilepsy and hepatic disease.

Interaction with other medicinal products and other forms of interaction

Reduced consciousness and respiratory depression is potentiated by ethanol, hypnotics, general anaesthetics (e.g. barbiturates), MAO inhibitors and psychotropic drugs with a sedative action (e.g. fentiazines), gabapentin, antiemetic medications, antihistamines, and other opioids. Dropizol should not be used with other morphine agonists/antagonists (buprenorphine, nalbuphine, pentazocine) because of their competitive receptor-binding that may aggravate withdrawal symptoms and reduce therapeutic effect.

Due to the ethanol content, Dropizol should not be used concomitantly with disulfiram or metronidazole. Both of these drugs can cause disulfiram-like reactions (flushing, rapid breathing, tachycardia).

Midazolam increases the analgesic effect of morphine and buprenorphine, and increases the respiratory depression effect of morphine. It is expected that Midazolam will interact similarly with other opioids.

Rifampicin induces CYP 3A4 in the liver thus increasing the metabolism of morphine, codeine and methadone. The effect of these opioids is thereby decreased or counteracted.

Cimetidine decreases the metabolism of morphine.

Morphine inhibits the glucuronidation of zidovudine in vitro.

Morphine’s duration of action may be reduced after taking fluoxetine.

Ethanol, see Section see 4.4.

Fertility, pregnancy and lactation


Should be used with caution in pregnant women. Should not be used during the third trimester due to drowsiness and respiratory depression or withdrawal symptoms in the neonate.


Dropizol should not be used during breastfeeding, as opium passes into human milk. The milk to plasma concentration ratio is 1:4.


As morphine has mutagenic propensity, it should be used for fertile women and men only if effective contraception is confirmed (see section 5.3).

Effects on ability to drive and use machines

Due to its undesirable effects, Dropizol may have a major influence on the ability to drive and use machines.

Undesirable effects

Cardiac disorders

Not known (cannot be estimated from the available data): Tachycardia, bradycardia

Nervous system disorders

Very common (≥1/10): Drowsiness

Common (≥1/100 to <1/10): Dizziness

Not known (cannot be estimated from the available data): Euphoria

Eye disorders

Common (≥1/100 to <1/10): Miosis

Respiratory, thoracic and mediastinal disorders

Common (≥1/100 to <1/10): Bronchospasms, cough decreased

Uncommon (≥1/1,000 to <1/100): Respiratory depression

Gastrointestinal disorders

Very common (≥1/10): Constipation, dry mouth

Common (≥1/100 to <1/10): Nausea, vomiting

Renal and urinary disorders

Common (≥1/100 to <1/10): Urinary retention

Uncommon (≥1/1,000 to <1/100): Urethral spasm

Skin and subcutaneous tissue disorders

Uncommon (≥1/1,000 to <1/100): Pruritus

Musculoskeletal and connective tissue disorders

Not known (cannot be estimated from the available data): Involuntary muscle contractions

Vascular disorders

Rare (≥1/10,000 to <1/1,000): Orthostatic hypotension

General disorders and administration site conditions

Common (≥1/100 to <1/10): Astenia

Hepatobiliary disorder

Uncommon (≥1/1,000 to <1/100): Hepatic enzymes increased

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via via the Yellow Card Scheme: Website: www.mhra.gov.uk/yellowcard.


Not applicable.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.